SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): November 13, 2003
Valeant Pharmaceuticals International
(Exact name of registrant as specified in its charter)
| | | | | |
Delaware
(State or other jurisdiction of
incorporation or organization) | | 1-11397
(Commission File Number) | | 33-0628076
(IRS Employer Identification
No.) |
3300 Hyland Avenue
Costa Mesa, California 92626
(Address of principal executive offices) (Zip Code)
(714) 545-0100
(Registrant’s telephone number, including area code)
TABLE OF CONTENTS
Item 5. Other Events and Regulation FD Disclosure.
November 13, 2003 Press Release
On November 13, 2003, Valeant Pharmaceuticals International issued a press release announcing its intention to offer, subject to market and other conditions, approximately $200 million principal amount of Convertible Subordinated Notes due 2010 and approximately $200 million principal amount of Convertible Subordinated Notes due 2013 (the “Notes”) to qualified institutional buyers in an offering exempt from registration pursuant to Rule 144A under the Securities Act of 1933. The November 13, 2003 press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference.
November 14, 2003 Press Release
On November 14, 2003, Valeant Pharmaceuticals International issued a press release announcing the pricing of its offering of the Notes. The sale of the Notes is expected to close on November 19, 2003. The November 14, 2003 press release is attached as Exhibit 99.2 to this report and is incorporated herein by this reference.
Item 7. Financial Statements,Pro FormaFinancial Information and Exhibits.
| | | | | |
| Exhibit Number | | Description | | |
| |
| | |
| 99.1 | | Press release dated November 13, 2003. | | |
| | | | | |
| 99.2 | | Press release dated November 14, 2003. | | |
-1-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | |
| Date: November 14, 2003 | | VALEANT PHARMACEUTICALS INTERNATIONAL |
| | | | | | | |
| | | By: | | /s/ Bary G. Bailey | | |
| | | | |
| | |
| | | | | Bary G. Bailey
Chairman and Chief Executive Officer | | |
-2-
EXHIBIT INDEX
| | | | | |
| Exhibit Number | | Description | | |
| |
| | |
| 99.1 | | Press release dated November 13, 2003. | | |
| | | | | |
| 99.2 | | Press release dated November 14, 2003. | | |
-3-
